Matches in SemOpenAlex for { <https://semopenalex.org/work/W2082854222> ?p ?o ?g. }
- W2082854222 abstract "Background In many countries of the industrialised world second generation ('atypical') antipsychotics have become the first line drug treatment for people with schizophrenia. The question as to whether, and if so how much, the effects of the various new generation antipsychotics differ is a matter of debate. In this review we examined how the efficacy and tolerability of ziprasidone differs from that of other second generation antipsychotics. Objectives To evaluate the effects of ziprasidone compared with other atypical antipsychotics for people with schizophrenia and schizophrenia‐like psychoses. Search methods We searched the Cochrane Schizophrenia Group Specialised Register (April 2007) and references of all identified studies for further trial citations. We contacted pharmaceutical companies and authors of trials for additional information. This search was updated July 2012, 254 citations added to awaiting classification section. Selection criteria We included all randomised, at least single‐blind, controlled trials comparing oral ziprasidone with oral forms of amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone or zotepine in people with schizophrenia or schizophrenia‐like psychoses. Data collection and analysis We extracted data independently. For continuous data, we calculated weighted mean differences (MD) for dichotomous data we calculated relative risks (RR) and their 95% confidence intervals (CI) on an intention‐to‐treat basis based on a random‐effects model. We calculated numbers needed to treat/harm (NNT/NNH) where appropriate. Main results The review currently includes nine randomised controlled trials (RCTs) with 3361 participants. The overall rate of premature study discontinuation was very high (59.1%). Data for the comparisons of ziprasidone with amisulpride, clozapine, olanzapine, quetiapine and risperidone were available. Ziprasidone was a less acceptable treatment than olanzapine (leaving the studies early for any reason: 5 RCTs, n=1937, RR 1.26 CI 1.18 to 1.35, NNH 7 CI 5 to 10) and risperidone (3 RCTs, n=1029, RR 1.11 CI 1.02 to 1.20, NNH 14 CI 8 to 50), but not than the other second generation antipsychotic drugs. Ziprasidone was less efficacious than amisulpride (leaving the study early due to inefficacy: 1 RCT, n=123, RR 4.72 CI 1.06 to 20.98, NNH 8 CI 5 to 50) olanzapine (PANSS total score: 4 RCTs, n=1291, MD 8.32 CI 5.64 to 10.99) and risperidone (PANSS total score: 3 RCTs, n=1016, MD 3.91 CI 0.27 to 7.55). Based on limited data there were no significant differences in tolerability between ziprasidone and amisulpride or clozapine. Ziprasidone produced less weight gain than olanzapine (5 RCTs, n=1659, MD ‐3.82 CI ‐4.69 to ‐2.96), quetiapine (2 RCTs, n=754, RR 0.45 CI 0.28 to 0.74) or risperidone (3 RCTs, n=1063, RR 0.49 CI 0.33 to 0.74). It was associated with less cholesterol increase than olanzapine, quetiapine and risperidone. Conversely ziprasidone produced slightly more extrapyramidal side‐effects than olanzapine (4 RCTs, n=1732, RR 1.43 CI 1.03 to 1.99, NNH not estimable) and more prolactin increase than quetiapine (2 RCTs, n=754, MD 4.77 CI 1.37 to 8.16), but less movement disorders (2 RCTs, n=822, RR 0.70 CI 0.51 to 0.97, NNT not estimable) and less prolactin increase (2 RCTs, n=767, MD ‐21.97 CI ‐27.34 to ‐16.60) than risperidone. Note: the 254 citations in the awaiting classification section of the review may alter the conclusions of the review once assessed. Authors' conclusions Ziprasidone may be a slightly less efficacious antipsychotic drug than amisulpride, olanzapine and risperidone. Its main advantage is the low propensity to induce weight gain and associated adverse effects. However, the high overall rate of participants leaving the studies early limits the validity of any findings." @default.
- W2082854222 created "2016-06-24" @default.
- W2082854222 creator A5002251483 @default.
- W2082854222 creator A5003496238 @default.
- W2082854222 creator A5016537819 @default.
- W2082854222 creator A5046445175 @default.
- W2082854222 creator A5051335014 @default.
- W2082854222 creator A5067357186 @default.
- W2082854222 creator A5068206298 @default.
- W2082854222 date "2009-10-07" @default.
- W2082854222 modified "2023-10-16" @default.
- W2082854222 title "Ziprasidone versus other atypical antipsychotics for schizophrenia" @default.
- W2082854222 cites W102941371 @default.
- W2082854222 cites W1496843021 @default.
- W2082854222 cites W1531159622 @default.
- W2082854222 cites W1591259115 @default.
- W2082854222 cites W1598602811 @default.
- W2082854222 cites W1904924604 @default.
- W2082854222 cites W1911611356 @default.
- W2082854222 cites W1964162160 @default.
- W2082854222 cites W1969447966 @default.
- W2082854222 cites W1969560316 @default.
- W2082854222 cites W1974446779 @default.
- W2082854222 cites W1976303732 @default.
- W2082854222 cites W1976706794 @default.
- W2082854222 cites W1977185679 @default.
- W2082854222 cites W1977497576 @default.
- W2082854222 cites W1977530428 @default.
- W2082854222 cites W1978040764 @default.
- W2082854222 cites W1980243692 @default.
- W2082854222 cites W1985335881 @default.
- W2082854222 cites W1988586706 @default.
- W2082854222 cites W1989448731 @default.
- W2082854222 cites W1992857340 @default.
- W2082854222 cites W1994033532 @default.
- W2082854222 cites W1997785005 @default.
- W2082854222 cites W1998544936 @default.
- W2082854222 cites W1998615066 @default.
- W2082854222 cites W1999646972 @default.
- W2082854222 cites W1999689270 @default.
- W2082854222 cites W1999808560 @default.
- W2082854222 cites W2002442062 @default.
- W2082854222 cites W200959462 @default.
- W2082854222 cites W2010732928 @default.
- W2082854222 cites W2013913914 @default.
- W2082854222 cites W2016333631 @default.
- W2082854222 cites W2018550650 @default.
- W2082854222 cites W2018613434 @default.
- W2082854222 cites W2020844317 @default.
- W2082854222 cites W2021799665 @default.
- W2082854222 cites W2023839473 @default.
- W2082854222 cites W2024355407 @default.
- W2082854222 cites W2026577398 @default.
- W2082854222 cites W2027873238 @default.
- W2082854222 cites W2027895008 @default.
- W2082854222 cites W2030026249 @default.
- W2082854222 cites W2031059010 @default.
- W2082854222 cites W2031474706 @default.
- W2082854222 cites W2032712358 @default.
- W2082854222 cites W2033431868 @default.
- W2082854222 cites W2033613811 @default.
- W2082854222 cites W2037155442 @default.
- W2082854222 cites W2041513331 @default.
- W2082854222 cites W2045228294 @default.
- W2082854222 cites W2046420174 @default.
- W2082854222 cites W2048989855 @default.
- W2082854222 cites W2049842299 @default.
- W2082854222 cites W2049994834 @default.
- W2082854222 cites W2050529946 @default.
- W2082854222 cites W2051304851 @default.
- W2082854222 cites W2051614606 @default.
- W2082854222 cites W2053301065 @default.
- W2082854222 cites W2055194104 @default.
- W2082854222 cites W2055396543 @default.
- W2082854222 cites W2058874144 @default.
- W2082854222 cites W2059444637 @default.
- W2082854222 cites W2062550117 @default.
- W2082854222 cites W2062834704 @default.
- W2082854222 cites W2063147623 @default.
- W2082854222 cites W2064027163 @default.
- W2082854222 cites W2064346475 @default.
- W2082854222 cites W2066617858 @default.
- W2082854222 cites W2074607197 @default.
- W2082854222 cites W2077001392 @default.
- W2082854222 cites W2077158449 @default.
- W2082854222 cites W2077418190 @default.
- W2082854222 cites W2077843362 @default.
- W2082854222 cites W2079068793 @default.
- W2082854222 cites W2081921819 @default.
- W2082854222 cites W2081978467 @default.
- W2082854222 cites W2082218913 @default.
- W2082854222 cites W2083252023 @default.
- W2082854222 cites W2083355457 @default.
- W2082854222 cites W2085360366 @default.
- W2082854222 cites W2086506558 @default.
- W2082854222 cites W2088408644 @default.
- W2082854222 cites W2088418924 @default.
- W2082854222 cites W2088753851 @default.
- W2082854222 cites W2090658963 @default.
- W2082854222 cites W2094210958 @default.